Orsolini U.,Volpe U. .2022 .. , : .
. .treatment aspects. J. Clin. Med, 11 : .
. .. , : .
Peritogiannis V.,Ninou A.,Samakouri M. .2022 .. , : .
. .understanding and management. Healthcare, 10 : .
. .. , : .
. .of schizophrenia and its management over 8-years period. , : .
. .using real-world data in Spain. BMC Psychiatry, 20 : .
Stockings E. .2018 .Global epidemiology and burden of. , : .
study .2016 .Schizophr. , 44 : 1195-1203.
Wulandari A.,All A. .2023 .. , : .
Arianti D .2024 .. Sanusi, : .
Cendikia Mandira . .. , 3 : 125-133.
.2017 .Theranostic biomarkers for schizophrenia. , : .
Int. J. Mol. Sci. . .. , 18 : .
Damanik R,Husada M.S. .2020 .. , : .
. .of gene polymorphism interferon gamma+874 A/T and. , : .
Med Maced. J. . .. , 8 : 70-75.
ARA. Balagtas T.,Poprawski T. .2022 .. , : .
Cureus ,AV ,Stepanov V.A.,Marusin A.V.,Kharkov V.N. . .. , 14 : .
Vagaitseva K.V. .2017 .. , : .
Genet Russ. J.,Lin P,Sun J.,Lou X.,Li D.,Shi Y. .2022 .. , 53 : 139-146.
. .clinical tests for schizophrenia. Gen. Psychiatry, 35 : .
. .. , : .
. Karimian S.S. .2018 .. T. Akbari, : .
. .in the Iranian patients. J. Hum. Genet. Genomics, 2 : .
. .. , : .
. Qin X,J.ChenandT.Zhou X .2020 .. , 22 : 11.
. .and schizophrenia. Acta Biochim. Biophys, 52 : 1181-1190.
. Guo X,Tang P.,Yang C.,Li R. .2018 .. , : .
Dis . .. , 33 : 89-97.
Gordon J.A.,Gogos J.A. .2016 .. , : .
J.ASN..M. . .VVerhooevern-DusifatndJ. mR.Ziankstnok, 2 : 021.
Sacchi S.,Pollegioni L. .2018 .. , : .
. .in a U87 glioblastoma cell line. PLoS ONE, 13 : .
. .. , 0196283 : .
. .Lack of association between proline dehydrogenase. , : .
. .(oxidase) 1 polymorphisms and schizophrenia in a Korean. , : .
Genet population. Psychiatric . .. , 22 : 153-154.
RH. Nadrich .2016 .. , : .
. .schizophrenia and bipolar disorder. Transl. Psychiatry, 6 : .
Wyse .2011 .. , 157 : .
Clelland CL . .. , 26 : 21-172.
CA. Pappas .2011 .Evidence for association of. , : .
outcome. Schizophr. Res. ,Caravaggio F. . .. , 131 : 139-145.
JK. Chung .2017 .. , : .
Kindler J,Boerrigter D. . .. , 43 : 23-777.
Galletly C. .2020 .. , : .
Réus GZ,Scaini G.,Petronilho F. . .. Mol. Psychiatry, 25 : 24-2872.
JP. Oses .2018 .The inhibition of the kynurenine. , : .
Psychiatry ,Abdullahi D.,Tripathi P.T.,Ronaldson P.T. .2018 .. , 81 : 25-63.
Physiol Am. J. Physiol. Cell,Nation D.A,M.D. Sweeney A.,Montagne A. . .. , 315 : 26-C356.
L.M. D'Orazio .2019 .Blood-brain barrier breakdown. , : .
Nat. Med. ,Kruse A.O.,JR. Bustillo A.O. .2022 .. , 25 : 27-276.
. .dysfunction in schizophrenia. Transl. Psychiatry, 12 : .
Kahn RS . .. , : 541398.
DR. Weinberger .2015 .. Nat. Rev. Dis., : .
Primers ,Song J,Viggiano A.,Monda M. .2014 .. , 67 : .
McCutcheon RA,Howes O.D. .2020 .ameta-analysis. Neuropsychobiology, 70 : 133-141.
Huang H.,Duan J. .2022 .symptoms and treatment. World Psychiatry, 19 : 15-33.
Madeira C,Alheira F.V. . .biomarkers for schizophrenia. Med, 2 : 32-416.
F.M. Tannos .2018 .Blood levels of glutamate and. , : .
Front. Psychiatry ,AS. Boyko S.A,Fedorenko O.Y.,Krotenko N.M. .2018 .. , 00713 : .
Semke A.V.,Bokhan N.A. .2014 .. , : .
J.D. .2019 .. , 10 : 80-85.
Bauminger ,Gaisler-Salomon .2022 .. , 24 : 35-642.
Mol schizophrenIinta..J.,Nakazawa K.,Jeevakumar V.,Nakao K. .2017 .. , 23 : .
. .leading to schizophrenia. npj Schizophr, 3 : .
Elmslie D.,Yoshikami D. .1985 .. , : 37.
Hilmas C,EF.R. Pereira M.,Alkondon A . .inthe frog spinal cord. Brain Res., 330 : 38-272.
Schwarcz R. .2001 .. , : .
. .metabolite kynurenic acid inhibits a7 nicotinic receptor. , : .
. .activity and increases non-a7 nicotinic receptor expression:. , : .
Neurosci Physiopathological implications.J.,Dobelis P,Cooper D.C. .2012 .. , 21 : 39-7473.
. .modulation of nicotinic acetylcholine alpha-7 receptor. , : .
. .. PLoS ONE, 7 : .
Perkins T.W.,Stone T.W. .1982 .. , 0041108 : .
Res acid. Brain,Konradsson-Geuken A,Wu H.Q. . .. , 247 : 41-187.
.2010 .. and A Campbell er a/, : .
Neuroscience ,Carpenedo R,Pittaluga A.,Cozzi S.,Attucci A . .. , 169 : 1848-1859.
Raiteri M.,Moroni F. .2001 .. , : .
Beggiato S.,Tanganelli K.,Fuxe T.,Antonelli T. . .. , 13 : 43-2147.
Ferraro and L. .2014 .Endogenous kynurenic acid regulates. , : .
Neuropharmacology . .. , 82 : 11-18.
Bruno R. Schwarczand J.P. .2009 .Astrocyte-derived kynurenic. , : .
Neurosci release. Eur.J.,Fazio F,Lionetto L,Curto M. . .. , 29 : 45-538.
M. Cavallari .2016 .. Xanthurenic acid activates mGlu2/3, : .
Chiappelli J,F.M. Notarangelo J . .markerfor schizophrenia. Sci.Rep, 5 : .
Kochunov and P. .2014 .Stress-induced increase in. , : .
Sellgren CM,Gracias J.,Jungholm O. . .. , 71 : 47-768.
.2019 .Peripheral and central levels of. , : .
. .healthy controls. , 9 : .
Rodriguez-Jimenez R . .. , : 48.
Santabarbara J.,A.l. Aparicio etal J. .2019 .. , : .
Schizophr. Res. ,Chess ,Alling T.E.,Bucci D.J. .2007 .MK. , 211 : 49-92.
. .working memory deficits. Schizophr. Bull, 33 : 797-804.